KWM Releases Doing Business in the U.S. (Chinese)

Current site :    US   |   EN
China Hong Kong SAR
United Kingdom
United States

From 2018 to 2019, China-U.S. relations have experienced ups and downs. The future of the China-U.S. trade agreement has become uncertain as the U.S. officially imposed a 25% tariff on USD200 billion worth of Chinese imports on 10 May 2019. Even against such a background, China-U.S. economic and trade cooperation still sees an inextricably intertwined and overlapping landscape of interests between the two countries.
The path of development is rarely smooth, but often tortuous. This is also the case for Chinese enterprises which expand globally and enter the U.S. market. For investors investing in the U.S., especially those from China, the reality of China-U.S. relations places higher requirements on risk prediction as well as an understanding and assessment of the economic, trade, political and legal environment of investments in the U.S.
In light of this, the partners and lawyers of KWM New York and Silicon Valley offices, who have been practicing attorneys in the U.S. for many years, have prepared the booklet "Doing Business in the U.S.", which covers foreign investment, incorporation, employment, government regulation, tax, dispute resolution and other issues. The booklet contains not only a basic introduction to various aspects of U.S. law, but also a collection of practical experience accumulated by the practitioners of KWM New York and Silicon Valley offices.
In such a rapidly changing world, we hope we can assist you in every challenge!

* KWM global network has produced a series publications in doing business overseas, which can also be accessed via website or intranet. These include:

"Doing Business in China" (EN) 

"Doing Business in Germany" (CN & EN) 

"Doing Business in Japan" (CN & EN)

"Doing Business in the UK" (CN & EN) 

"Doing Business in Spain" (CN) 

"Doing Business in the Middle East" (CN & EN) 

"Doing Business in Korea" (CN & EN)

Doing Business in the U.S.
This publication introduces the critical issues foreign enterprises might meet in investing in the US and interprets legal documents in specific areas. This publication is in Chinese only.


2.65MB, 62 Pages

New regulations in China designed to encourage innovation in clinical trials have made it easier to test human samples in a lab setting.

19 May 2022

In light of Australia’s sanctions on the Russian Federation, it is in every Australian business’ interest to be prepared to pivot in response to this changing landscape.

21 March 2022

This article was written by Nick Davies and Laura Luo

03 September 2021